| Name | Title | Contact Details |
|---|
Touchstone Medical Imaging, LLC is a leading provider of diagnostic imaging services in the United States. Headquartered in Brentwood, Tennessee, Touchstone owns and operates diagnostic imaging facilities nationwide.
Since 1949, Gracepoint has cared for people like Rachel who needed a combination of intense therapies combined into her school day to thrive, graduate and find a job she loves. At Gracepoint, adults and children and their families have access to 26 board-certified psychiatrists, therapeutic specialists and 26 locations throughout Tampa Bay. Gracepoint`s mission is educating, advocating and giving hope to people touched by behavioral health and developmental challenges.
Pain Treatment Centers of America is a comprehensive pain management clinic that offers both opioid and non-opioid medical management, as well as an array of minimally invasive pain management techniques.
Crawford County Mental Health Center is a community mental health center that provides mental health and substance abuse services to adults and children in Crawford County, Kansas.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.